Marinus Pharmaceuticals Inc (NASDAQ:MRNS) – Equities researchers at Oppenheimer issued their FY2021 earnings per share estimates for shares of Marinus Pharmaceuticals in a research note issued on Thursday, December 19th. Oppenheimer analyst J. Olson expects that the biopharmaceutical company will earn ($0.50) per share for the year. Oppenheimer has a “Outperform” rating and a $6.00 price objective on the stock.
A number of other research firms have also recently weighed in on MRNS. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $5.00 price objective on shares of Marinus Pharmaceuticals in a research report on Monday, November 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Marinus Pharmaceuticals in a research report on Friday, October 18th. ValuEngine lowered Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Zacks Investment Research cut Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 12th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Marinus Pharmaceuticals in a research report on Wednesday, November 13th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Marinus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $5.78.
Marinus Pharmaceuticals stock opened at $2.33 on Monday. The company’s 50 day simple moving average is $1.34 and its 200-day simple moving average is $2.02. Marinus Pharmaceuticals has a 1 year low of $0.77 and a 1 year high of $5.40. The company has a market capitalization of $116.90 million, a price-to-earnings ratio of -2.59 and a beta of 2.87.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.02).
Large investors have recently bought and sold shares of the business. BlackRock Inc. raised its stake in shares of Marinus Pharmaceuticals by 7.2% in the second quarter. BlackRock Inc. now owns 3,427,739 shares of the biopharmaceutical company’s stock valued at $14,226,000 after acquiring an additional 229,811 shares in the last quarter. Morgan Stanley boosted its holdings in Marinus Pharmaceuticals by 1,679.6% in the second quarter. Morgan Stanley now owns 187,889 shares of the biopharmaceutical company’s stock valued at $780,000 after purchasing an additional 177,331 shares during the period. Vanguard Group Inc. boosted its holdings in Marinus Pharmaceuticals by 4.7% in the second quarter. Vanguard Group Inc. now owns 2,587,314 shares of the biopharmaceutical company’s stock valued at $10,737,000 after purchasing an additional 115,294 shares during the period. State Street Corp grew its stake in Marinus Pharmaceuticals by 4.9% during the 3rd quarter. State Street Corp now owns 931,433 shares of the biopharmaceutical company’s stock worth $1,434,000 after purchasing an additional 43,425 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in Marinus Pharmaceuticals by 199.6% during the 2nd quarter. Wells Fargo & Company MN now owns 52,642 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 35,072 shares in the last quarter. Institutional investors and hedge funds own 57.99% of the company’s stock.
In other Marinus Pharmaceuticals news, CEO Scott Braunstein purchased 100,000 shares of Marinus Pharmaceuticals stock in a transaction dated Friday, December 13th. The shares were acquired at an average price of $1.62 per share, with a total value of $162,000.00. 5.10% of the stock is currently owned by corporate insiders.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.